Cardiologia Clínica Integral - 11560 Ciudad de México

• Cardióloga Egresada del Hospital de Cardiología Centro Médico Siglo XXI

• Postgrado en Cuidado del Paciente Crítico Cardiológico, en el Hospital Universitario de Alberta Edmonton Canadá

• Postgrado en Investigación Clínica Cardiovascular en el Hospital Veterans Affairs en Amarillo Texas

• Miembro titular de la Asociación Mexicana de Cardiología

• Médico consultor en Ayurveda, acreditada por la Asociación Americana de Maharishi Ayurveda en Fairfield Iowa.

• Miembro de la Sociedad de Medicina Integrativa y Holística en Estados Unidos

• Más de 30 publicaciones relacionadas a aspectos clínicos, de manejo de la enfermedad y de Economía de la Salud

Publicaciones

Héctor Arreola-Ornelas, Lourdes García-Mollinedo, Alfonso Rosado-Buzzo, Javier Dorantes-Aguilar, Emilio Muciño-Ortega, Joaquín Mould-Quevedo. Coste-efectividad de dalteparina en la profilaxis y manejo de la enfermedad tromboembólica venosa (ETV) asociada al paciente adulto médico y quirúrgico en México. PharmacoEconomics - Spanish Research Articles 2010; 7 (3): 118-132.

Jerjes-Sánchez C, Ramírez-Rivera A, de Lourdes García M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, Pierzo JA, Rosas E. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. J Thromb Thrombolysis. 1995; 2(3):227-229.

Jerjes Sánchez C; Gutiérrez-Fajardo P; Ramírez-Rivera A; García-Mollinedo Mde L; Hernández Chávez G. Acute infarct of the right ventricle secondary to a massive pulmonary thromboembolism. Arch Inst Cardiol Mex; 65(1): 65-73, 1995 Jan-Feb.

García-Mollinedo Mde L; Jerjes-Sánchez C; Ruiz de Chávez Cervantes A. Re-evaluating the noninvasive reperfusion criteria in patients with AMI undergoing pharmacological thrombolysis (part I). Arch Inst Cardiol Mex; 63(5): 463-8, 1993 Sep-Oct.

García-Mollinedo Mde L; Jerjes-Sánchez C; de Chávez Cervantes AR. Reassessment of the noninvasive reperfusion criteria in AMI patients submitted to pharmacological thrombolysis (part II). Arch Inst Cardiol Mex; 63(6): 563-5, 1993 Nov-Dec.

Héctor Arreola Ornelas, Alfonso Rosado Buzzo, Lourdes García, Javier Dorantes Aguilar, Iris Contreras Hernández, Joaquín F Mould Quevedo. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico. Reumatología clinica. 2012; 8(3):120-7.

Héctor Arreola-Ornelas, Alfonso Rosado-Buzzo, Lourdes García-Mollinedo, Javier Dorantes Aguilar, Emilio Muciño-Ortega, Joaquín Federico Mould-Quevedo. Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social. Cir Cir 2012; 80(5):411-8.

Arreola-Ornelas H, García-Mollinedo L, Rosado Buzzo A, Mould-Quevedo J, Dávila-Loaiza G. Ahorro por el manejo con Sildenafil como coadyuvante en la adherencia al tratamiento farmacológico en hipertensión y diabetes tipo 2 en México. Rev Mex Urol 2008; 68(1):21-35.

Rosado-Buzzo A1, Garcia-Mollinedo L1, Camacho-Cordero L1, Roberts CS2, Mould-Quevedo JF2, Trejo-Martinez A1, Luna-Casas G1, 1Links & Links S.A, de C.V., México D.F., México, 2Pfizer Inc, New York, NY, USA. MORBIDITY AND MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA IN ADULTS IN SIX COUNTRIES IN LATIN AMERICA. Value in Health 2011; 14 (7): A540-A541.

Rosado-Buzzo A1, Garcia-Mollinedo L1, Camacho-Cordero L1, Roberts CS2, Mould-Quevedo JF2, Trejo-Martinez A1, Luna-Casas G1, 1Links & Links S.A, de C.V., México D.F., México, 2Pfizer Inc, New York, NY, USA. ECONOMIC IMPACT OF COMMUNITY ACQUIRED PNEUMONIA HOSPITALIZATIONS IN ADULTS IN SIX COUNTRIES IN LATIN AMERICA. Value in Health 2011; 14 (7): A559.

Arreola-Ornelas H1, Rosado-Buzzo A1, García-Mollinedo L1, Dorantes-Aguilar J1, Muciño-Ortega E2, Mould-Quevedo JF2, 1Links & Links, Mexico City, Mexico, 2Pfizer S.A. de C.V., México City, Mexico. COST-EFFECTIVENESS OF DALTEPARIN IN THE MANAGEMENT OF UNSTABLE ANGINA/NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (UA/NSTEMI) EVENTS IN ADULT PATIENTS IN MEXICO. Value in Health 2010; 13 (3): A164.

Arreola-Ornelas H1, Rosado-Buzzo A1, García-Mollinedo L1, Dorantes-Aguilar J1, Muciño-Ortega E2, Mould-Quevedo JF22, 1Links & Links, Mexico City, Mexico, 2Pfizer S.A. de C.V., México City, Mexico. A PHARMACOECONOMICS ASSESSMENT OF SILDENAFIL IN THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION IN PEDIATRICS: THE MEXICAN CASE. Value in Health 2010; 13 (3): A164.

Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2 , Dorantes-Aguilar J1, Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2 Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. A COST-EFFECTIVENESS ASSESSMENT OF DALTEPARIN AS A PROPHYLACTIC AND THERAPEUTIC AGENT FOR THE MANAGEMENT OF THROMBOEMBOLIC VENOUS DISEASE (VTE) IN MEXICAN ADULT PATIENTS AFTER TOTAL HIP REPLACEMENT. Value in Health 2009; 12 (3): A150.

Arreola-Ornelas H1 , Rosado-Buzzo AA2, García-Mollinedo MDL2 , Dorantes-Aguilar J1, Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. ECONOMIC EVALUATION OF DALTEPARIN FOR THE MANAGEMENT OF THROMBOEMBOLIC VENOUS DISEASE (VTE) AFTER TOTAL KNEE ARTHROPLASTY IN MEXICO. Value in Health 2009; 12 (3): A150.

Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2 , Dorantes-Aguilar J1, Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. COST CONSEQUENCES ANALYSIS OF ANTITHROMBOTIC THERAPIES FOR VENOUS THROMBOEMBOLIC DISEASE (VTE) IN MEDICAL PATIENTS IN MEXICO. Value in Health 2009; 12 (3): A150.

Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2 , Dorantes-Aguilar J1, Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. A PHARMACOECONOMIC ANALYSIS OF PROPHYLAXIS THERAPIES AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN MEXICAN PATIENTS WITH CANCER. Value in Health 2009; 12 (3): A151.

Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2,Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. ECONOMIC ASSESSMENT OF SILDAFENIL FOR THE MANAGEMENT OF PATIENTS WITH ERECTILE DYSFUNCTION (ED) SECONDARY TO DIABETES MELLITUS TYPE 2 (DM2) AND HYPERTENSION IN MEXICO. Value in Health 2008; 11 (3): A247.

Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2,Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. COST-EFFECTIVENESS ASSESSMENT OF ANTIEPILEPTIC DRUGS AS ADJUVANT TREATMENTS FOR THE MANAGEMENT OF REFRACTORY PARTIAL SEIZURES IN ADULT MEXICAN PATIENTS. Value in Health 2008; 11 (3): A140.

Arreola Ornelas H1, Rosado Buzzo A2, García Mollinedo L2, Camacho LM2, Lechuga D3. 1OikoSalud y Fundación Mexicana para la Salud, Mexico City, Mexico, 2OikoSalud, Mexico City, Mexico, 3Roche Mexico, Mexico City, Mexico. COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB+PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY). Value in Health 2011; 14 (7): A451.

Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2, Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. THE ECONOMIC IMPACT OF SINGLE-DOSE AZITHROMYCIN MICROSPHERES FORMULATION FOR THE MANAGEMENT OF ACUTE STREPTOCOCCAL PHARYNGITIS (ASP) IN MEXICO. Value in Health 2008; 11 (3): A100.

Arreola-Ornelas H1, Rosado-Buzzo A1, García-Mollinedo L1, Dorantes-Aguilar J1, Muciño-Ortega E2, Mould-Quevedo JF2. 1Links & Links, Mexico City, Mexico, 2Pfizer S.A. de C.V., México City, Mexico. COST-EFFECTIVENESS OF SILDENAFIL IN THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION IN MEXICAN ADULT PATIENTS. Value in Health 2010; 13 (3): A5.

Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2,Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO. Value in Health 2008; 11 (3): A17 – A18.

Arreola-Ornelas H1, Rosado-Buzzo A1, García-Mollinedo L1, Dorantes-Aguilar J1, Muciño-Ortega E2, Mould-Quevedo JF2. 1Links & Links, Mexico City, Mexico, 2Pfizer S.A. de C.V., México City, Mexico. COST-EFFECTIVENESS ANALYSIS OF CELECOXIB FOR THE MANAGEMENT OF LOW BACK PAIN AT THE SOCIAL SECURITY MEXICAN INSTITUTE. Value in Health 2010; 13 (3): A210.

Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2 ,Dorantes-Aguilar J1, Mould-Quevedo J Q3, Davila-Loaiza G3. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. PREGABALIN FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDERS (GAD) – A COST-EFFECTIVENESS CASE STUDY OF MEXICO. Value in Health 2009; 12 (3): A176.

Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Muciño-Ortega E3,Mould-Quevedo JF4, Galindo-Suarez RM3. 1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Pfizer, Mexico City, Mexico, 4Pfizer, New York, NY, USA. ECONOMIC EVALUATION OF SEQUENTIAL ANALGESIC TREATMENT IN THE MANAGEMENT OF MODERATE ANKLE SPRAIN IN MEXICAN ADULTS. Value in Health 2011; 14 (3): A62.

Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Camacho-Cordero L2, Muciño-Ortega E3, Galindo-Suarez RM3, Mould-Quevedo JF4. 1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Pfizer, Mexico City, Mexico, 4Pfizer, New York, NY, USA. COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS. Value in Health 2011; 14 (3): A76.

Arreola Ornelas H1, Rosado Buzzo A2, García Mollinedo L2, Camacho LM2, Lechuga D.3. 1OikoSalud y Fundación Mexicana para la Salud, Mexico City, Mexico, 2OikoSalud, Mexico City, Mexico, 3Roche Mexico, Mexico City, Mexico. COMPARATIVE ANALYSIS OF COST-EFFECTIVENESS BEVACIZUMAB+PACLITAXEL VERSUS USING ONLY VERSUS PACLITAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN IN MEXICO PUBLIC INSURANCE (SEGURO POPULAR). Value in Health 2011; 14 (7): A448 – A449.

Arreola-Ornelas H1, Rosado-Buzzo A2, García-Mollinedo L2, Dorantes-Aguilar J2, Lemus-Carmona E3. 1OikoSalud and Fundación Mexicana para la Salud (FUNSALUD), Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Novartis Pharmaceuticals Corporation, Mexico City, Mexico. COST- EFFECTIVENESS OF RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR WET AGE-RELATED MACULAR DEGENERATION (NAMD) AT THE MEXICAN SOCIAL SECURITY SYSTEM (IMSS). Value in Health 2012; 15 (4): A251.

Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Camacho L2, Mould-Quevedo JF3, Muciño-Ortega E4, Galindo-Suarez RM4. 1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico City, Mexico, 3Pfizer, New York, NY, USA, 4Pfizer, Mexico City, Mexico. COST-EFFECTIVENESS OF TEMSIROLIMUS FOR METASTIC RENAL-CELL CARCINOMA AND POOR PROGNOSIS PATIENTS IN MEXICO. Value in Health 2011; 14 (3): A164.

Arreola-Ornelas H1, Rosado-Buzzo AA2, García-Mollinedo MDL2 ,Dorantes-Aguilar J1, Mould-Quevedo J Q3, Davila-Loaiza G3. Value in Health 2009; 12 (3): A176. 1Fundación Mexicana para la Salud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico. COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA: A MEXICAN PERSPECTIVE. Value in Health 2009; 12 (3): A133 – A134.